SCHEMBL4675665

SCHEMBL4675665

CC(=O)c1ccc(Cn2cc(C(=O)O)cc2C(=O)C=C(O)c2nn[nH]n2)cc1

nearest known ligand 0.37

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
XDH P47989 1/20 0.37
P2RY14 Q15391 2/20 0.36
ALDH1A1 P00352 1/20 0.34
MAPK10 P53779 1/20 0.34
ERCC5 P28715 1/20 0.32
FEN1 P39748 1/20 0.32
KDM1A O60341 1/20 0.31
MAOB P27338 1/20 0.31
RCOR1 Q9UKL0 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4676062 0.93 XDH (0.36) XDHP2RY14ALDH1A1MAPK10ERCC5
SCHEMBL4672844 0.91 P2RY14 (0.35) P2RY14
SCHEMBL4671402 0.89 CA12 (0.42) P2RY14
SCHEMBL4670862 0.89 UCHL5 (0.32) ALDH1A1MAPK10ERCC5FEN1
SCHEMBL4677658 0.88 EGLN1 (0.39) MAPK10
SCHEMBL4677380 0.88 CCNC (0.37) P2RY14MAPK10ERCC5FEN1
SCHEMBL4679403 0.87 CA12 (0.42) XDHP2RY14ERCC5FEN1
SCHEMBL4671002 0.87 CES1 (0.39) XDH
SCHEMBL4673555 0.84 MCL1 (0.35) P2RY14
SCHEMBL4672483 0.84 ALDH1A1 (0.36) P2RY14ALDH1A1MAPK10KDM1AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 XDH 112/4885P2RY14 3108/4885ALDH1A1 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.